First Eagle Investment Management LLC Buys Shares of 29,300 ICU Medical, Inc. (NASDAQ:ICUI)

First Eagle Investment Management LLC purchased a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 29,300 shares of the medical instruments supplier’s stock, valued at approximately $3,479,000.

A number of other hedge funds also recently made changes to their positions in ICUI. Innealta Capital LLC bought a new position in ICU Medical in the 2nd quarter worth approximately $32,000. Motco acquired a new position in ICU Medical during the 1st quarter worth $29,000. GAMMA Investing LLC boosted its position in ICU Medical by 75.1% during the 1st quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 133 shares during the period. EntryPoint Capital LLC grew its stake in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 395 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 173 shares during the period. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the sale, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares in the company, valued at approximately $645,901.02. The disclosure for this sale can be found here. Insiders sold a total of 28,552 shares of company stock worth $4,537,802 over the last ninety days. 6.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Raymond James increased their target price on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Thursday, August 8th. StockNews.com raised ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Finally, KeyCorp lifted their target price on ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.00.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $176.74 on Friday. The company has a market capitalization of $4.31 billion, a PE ratio of -72.14 and a beta of 0.65. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 2.41. The stock has a fifty day moving average of $149.89 and a 200-day moving average of $121.37. ICU Medical, Inc. has a one year low of $78.28 and a one year high of $181.87.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.00 by $0.56. The business had revenue of $596.50 million during the quarter, compared to the consensus estimate of $556.64 million. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. ICU Medical’s revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.58 earnings per share. As a group, equities analysts anticipate that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.